The purpose of this study was to test the type and the degree of cytotoxic effects of epirubicin and radiation in combined treatment on Chinese hamster lung cells in vitro. Experiments were performed with proliferating tissue culture cells. Cell kill was determined by colony-forming ability. The maximum killing effects were obtained when simultaneous action of drug treatment and irradiation occurred. Their interaction was synergistic. Synergism depended on time of drug incubation (epirubicin present for 1 h). Slight antagonism was noted after prolonged drug action (24 h).
Get full access to this article
View all access options for this article.
References
1.
ArcamoneF., PencoS., VigevaniA., RedaelliS., FranchiG., Di MarcoA., CasazzaA.M., DasdiaT., FormelliF., NeccoA., SoranzoG.: Synthesis and antitumor properties of new glycosides of daunomycinone and adriamycinone.J. Med. Chem., 18: 703–707, 1975.
2.
ArcamoneF., Di MarcoA., CasazzaA.M.: Chemistry and pharmacology of new antitumor anthracyclines. In: Advances in Cancer Chemotherapy, pp. 297–312. UmezawaH. (eds.), Japan Sci. Soc. Press, Tokyo, 1978.
3.
BanJ., OlahE., WeberG.: Action of lycurim and pyrazofurin on hepatoma 3924A cells in culture.Cancer Treat. Rep., 66: 343–349, 1982.
4.
BanJ., BistrovićM., MaričićŽ., KolarićK.: Interaction of 4′-epi-doxorubicin and radiation in combined treatment on hamster lung cells. In: CMEA Chemotherapy Symposium, 1984, pp. 449–455, EckhardtS., and Kerpel-FroniusS. (eds.), Akademiai Kiado, Budapest, 1985.
5.
BerenbaumM.C.: Criteria for analysing interactions between biologically active agents. In: Advances in Cancer Research, vol. 35, pp. 269–336. KleinG., WeinhouseS. (eds.), Academic Press, New York, 1981.
6.
BistrovićM., NagyB., MaričićŽ., KolarićK.: Interaction of adriamycin and radiation in combined treatment on mouse L-cells.Eur. J. Cancer, 14: 411–414, 1978.
7.
BistrovićM., NagyB., MaričićŽ.: The repair of radiation injury in L-cells treated by adriamycin.Eur. J. Cancer, 16: 333–338, 1980.
8.
CasazzaA.M., Di MarcoA., BonadonnaG., BonfanteV., BertazzoliC., BelliniO., PratesiG., SalaL., BalleriniL.: Effects of modifications in position 4 of the chromophore or in position 4′ of the aminosugar, on the antitumor activity and toxicity of daunorubicin and doxorubicin. In: Anthracyclines - Current Status and New Developments, pp. 403–430. CrookeS.T., and ReichS.D. (eds.), Academic Press, New York, 1980.
9.
CasazzaA.M., GiulianiF.C.: Preclinical properties of epirubicin. In: Advances in Anthracycline Chemotherapy: Epirubicin, pp. 31–40, BonadonnaG. (ed.), Masson Italia, Milan, 1984.
10.
Di MarcoA., CasazzaA.D., DasdiaT., NeccoA., PratesiG., RivoltaP., VelchichA., ZaccaraA., ZuninoF.: Changes of activity of daunorubicin, adriamycin and stereoisomers following the introduction or removal of hydroxyl groups in the amino sugar moiety.Chem. Biol. Interact., 19: 291–302, 1977.
11.
GiulianiF.C., KaplanN.O.: New doxorubicin analogs active against doxorubicin-resistant colon tumor xenografts in the nude mouse.Cancer Res., 40: 4682–4687, 1980.
12.
GiulianiF.C., CoirinA.K., RiceM.R., KaplanN.O.: Effects of 4′-doxorubicin analogs on heterotransplantation of human tumors in congenitally athymic mice.Cancer Treat. Rep., 65: 1063–1075, 1981.
13.
HellmanS., HannonE.: Effects of adriamycin on the radiation response on murine hematopoietic stem cells.Radiat. Res., 67: 162–168, 1976.
14.
HillB., WhelanR.D.H.: A comparison of the lethal and kinetic effects of doxorubicin and 4-epi-doxorubicin in vitro.Tumori, 68: 29–37, 1982.
15.
KolarićK., RothA., BanJ., DujmovićI.: Combination of 4′-epi-doxorubicin and radiation in the treatment of inoperable esophageal cancer - A preliminary report. In: CMEA Chemotherapy Symposium, 1984, pp. 465–469. EckhardtS., and Kerpel-FroniusS. (eds.), Akademiai Kiado, Budapest, 1985.
16.
NagyB., BistrovićM., MaričićŽ.: Adriamycin and X-ray damage interaction in Chinese hamster cells. In: Tumor Biology and Therapy.BroerseJ.J., BarendsenG.W., KalH.B., Van der KogelA.J. (eds.), Proceedings of the Seventh International Congress of Radiation Research, Martinus Nijhoff, Amsterdam, 1983.
17.
NeidleS.: A hypothesis concerning possible new derivatives of daunorubicin and adriamycin with enhanced DNA-binding properties.Cancer Treat. Rep., 61: 928–929, 1977.
18.
SalmonS.E., Liu RosaM., CasazzaA.M.: Evaluation of new anthracycline analogs with the human tumor stem cell assay.Cancer Chemother. Pharmacol., 6: 103–110, 1981.
19.
TaetleR., HowellS.B., GiullianiF.C., KoziolS., KoesslerA.: Comparison of the activity of doxorubicin analogues using colony-forming assay and human xenografts.Cancer, 50: 1455–1461, 1982.
20.
VillaniF., FavalliL., PiccininiF.: Relationship between the effect on calcium turnover and early cardiotoxicity of doxorubicin and 4′-epi-doxoru-bicin in guinea pig heart muscle.Tumori, 66: 689–697, 1980.
21.
WatringW.G., ByefieldL.D., LagasseY.D., LeeG., JuillardM.J., SmithM.L.: Combination adriamycin and radiation therapy in gynecologic cancers.Gynecol., Oncol., 2: 518–603,1974.
